The Underlying Mechanisms and Emerging Strategies to Overcome Resistance in Breast Cancer
Cancers · 08.09.2025 · 17 (17) · 2938
DOI: 10.3390/cancers17172938 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 08.09.2025. Verfasst von Krishnaswamy Kannan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Biomolecular Integrations, Little Rock, AR 72205, USA. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 319 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NASA-EPSCoR-Arkansas Space Grant Consortium; Arkansas Research Alliance, Arkansas Research Alliance, University of Arkansas.
Abstract (Originalsprache)
Despite advances in early detection and targeted therapies, breast cancer (BC) remains a leading cause of cancer-related mortality among women worldwide. Resistance develops through the interplay of tumor-intrinsic heterogeneity and tumor-extrinsic influences, including the tumor microenvironment and immune–metabolic interactions. This complexity drives therapeutic evasion, metastatic progression, and poor outcomes. Resistance mechanisms include drug efflux, genetic mutations, and altered signaling pathways. Additional contributors are cancer stem cell plasticity, exosomal RNA transfer, stromal remodeling, epigenetic alterations, and metabolic reprogramming. Microbial influences and immune evasion further reduce treatment effectiveness. Collectively, these processes converge on regulated cell death (RCD) pathways—apoptosis, ferroptosis, and pyroptosis—where metabolic shifts and immune suppression recalibrate cell death thresholds. Nutrient competition, hypoxia-driven signaling, and lactate accumulation weaken antitumor immunity and reinforce resistance niches. In this review, we synthesize the genetic, metabolic, epigenetic, immunological, and microenvironmental drivers of BC resistance within a unified framework. We highlight the convergence of these mechanisms on RCD and immune–metabolic signaling as central principles. Artificial intelligence (AI) is emphasized as a cross-cutting connector that links major domains of resistance biology. AI supports early detection through ctDNA and imaging, predicts efflux- and mutation-driven resistance, models apoptotic and ferroptotic vulnerabilities, and stratifies high-risk patients such as TNBC patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Biomolecular Integrations, Little Rock, AR 72205, USA.
- Nanobio Diagnostics, West Chester, PA 19382, USA.
- Department of Dermatology, University of California-Irvine, Irvine, CA 92697, USA.
- Department of Biology, Donaghey College of Science, Technology, Engineering, and Mathematics, University of Arkansas at Little Rock, Little Rock, AR 72204, USA.
ORCID-Profile: Nawab Ali
Förderung
- NASA-EPSCoR-Arkansas Space Grant Consortium; Arkansas Research Alliance
- Arkansas Research Alliance
- University of Arkansas
- NASA-EPSCoR-Arkansas Space Grant Consortium
Zitieren
APA
Kannan, K., Srinivasan, A., Kannan, A., & Ali, N. (2025). The Underlying Mechanisms and Emerging Strategies to Overcome Resistance in Breast Cancer. Cancers, 17(17), 2938. https://doi.org/10.3390/cancers17172938
Vancouver
Kannan K, Srinivasan A, Kannan A, Ali N. The Underlying Mechanisms and Emerging Strategies to Overcome Resistance in Breast Cancer. Cancers. 2025;17(17):2938. doi:10.3390/cancers17172938
BibTeX
@article{Kannan2025,
author = {Kannan, Krishnaswamy and Srinivasan, Alagarsamy and Kannan, Aarthi and Ali, Nawab},
title = {The Underlying Mechanisms and Emerging Strategies to Overcome Resistance in Breast Cancer},
journal = {Cancers},
year = {2025},
volume = {17},
number = {17},
pages = {2938},
doi = {10.3390/cancers17172938}
}
EUVIMED